SEC Comment Letter 0000000000-25-002399 to Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc.
Date: March 4, 2025 · CIK: 0001649989 · Accession: 0000000000-25-002399
AI Filing Summary & Sentiment
File numbers found in text: 333-285438
Letter
March 4, 2025 Lawrence A. Kenyon Chief Financial Officer and Interim Chief Executive Officer Outlook Therapeutics, Inc. 111 S. Wood Avenue, Unit #100 Iselin, New Jersey 08830 Re:Outlook Therapeutics, Inc. Registration Statement on Form S-3 Filed February 28, 2025 File No. 333-285438 Dear Lawrence A. Kenyon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Courtney M.W. Tygesson
Show Raw Text
March 4, 2025
Lawrence A. Kenyon
Chief Financial Officer and Interim Chief Executive Officer
Outlook Therapeutics, Inc.
111 S. Wood Avenue, Unit #100
Iselin, New Jersey 08830
Re:Outlook Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 28, 2025
File No. 333-285438
Dear Lawrence A. Kenyon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Courtney M.W. Tygesson